Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADCYAP1
REST API REST API
Homo sapiens
ADCYAP1 is differentially expressed in 169 experiments: 82 organism parts: hypothalamus, brain, ... (80 more);, 94 disease states: normal, Parkinson's disease, ... (92 more);, 42 cell types 212 cell lines 17 compound treatments and 56 other conditions.
Synonyms PACAP
Orthologs ADCYAP1 (Gallus gallus)   Adcyap1 (Mus musculus)   adcyap1a (Danio rerio)   adcyap1b (Danio rerio)   A4FV02_BOVIN (Bos taurus)   adcyap1 (Xenopus laevis)   ADCYAP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuropeptide hormone activity, receptor signaling protein activity, extracellular region, receptor binding, cell-cell signaling, transmembrane receptor protein tyrosine kinase signaling pathway, soluble fraction, hormone activity, regulation of G-protein coupled receptor protein signaling pathway, negative regulation of cell cycle, signal transduction, activation of adenylate cyclase activity, female pregnancy, nerve growth factor receptor signaling pathway, peptide hormone receptor binding
InterPro Term Glucagon_GIP_secretin_VIP
UniProt Accession Q53BH6, Q53BH1, P18509, B7Z222
Search EB-eye ENSG00000141433
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-1577, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-GEOD-19639, E-GEOD-2450, ... (23 experiments)

Factor Value U/D Experiments
SW480
2
E-MEXP-1014, E-MTAB-37
Jurkat
1
2
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
A7
1
1
E-MTAB-37
EM2
1
E-MTAB-37
SEM
1
E-MTAB-37
MKN7
1
E-GEOD-15460
206 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-13987, E-GEOD-11755, E-GEOD-21909, E-GEOD-21750, ... (27 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
cancer cell culture
1
E-GEOD-14990
CD4+ T cell
7
1
E-MTAB-24
n/a
1
E-MTAB-24
adipose stem cells derived from adult human donor
1
E-GEOD-20033
platelet
1
E-GEOD-2006
36 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, ... (34 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
lung adenocarcinoma
2
E-MTAB-37, E-GEOD-4127
extranodal NK/T-cell lymphoma
1
E-GEOD-19067
testicular seminoma
1
E-GEOD-8607
oligodendroglioma
1
E-GEOD-4290
benign prostatic hyperplasia
1
E-MEXP-2034
88 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-6907, E-GEOD-5741, ... (11 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-412, E-GEOD-7307, E-GEOD-2803
ponasterone A
1
E-GEOD-3113
vanadium pentoxide
1
E-GEOD-5339
ox-LDL
1
E-GEOD-5741
glutamine
1
E-MEXP-1335
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
11 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
85
1
1
E-GEOD-3494
85 years
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

Developmental stage
studied in E-GEOD-19743, E-GEOD-2666, E-GEOD-4667, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011

Genotype
studied in E-GEOD-21750, E-TABM-321, E-GEOD-1153, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-9764, E-GEOD-20505

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (25 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Phenotype
studied in E-GEOD-22309, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246

RNAi
studied in E-MEXP-1509, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-6532

Processing time: 0.514 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM